On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity
mBio · 2024
DOI: 10.1128/mbio.00966-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Rebecca C S Edgar und 22 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Deakin University, Geelong, Australia. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium falciparum, Plasmodium vivax, Aminopeptidases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DHAC | National Health and Medical Research Council (NHMRC), Therapeutic Innovation Australia (TIA).
Abstract (Originalsprache)
To combat the global burden of malaria, development of new drugs to replace or complement current therapies is urgently required. Here, we show that the compound MMV1557817 is a selective, nanomolar inhibitor of both Plasmodium falciparum and Plasmodium vivax aminopeptidases M1 and M17, leading to inhibition of end-stage hemoglobin digestion in asexual parasites. MMV1557817 can kill sexual-stage P. falciparum , is active against murine malaria, and does not show any shift in activity against a panel of parasites resistant to other antimalarials. MMV1557817 -resistant P. falciparum exhibited a slow growth rate that was quickly outcompeted by wild-type parasites and were sensitized to the current clinical drug, artemisinin. Overall, these results confirm MMV1557817 as a lead compound for further drug development and highlights the potential of dual inhibition of M1 and M17 as an effective multi-species drug-targeting strategy. IMPORTANCE Each year, malaria infects approximately 240 million people and causes over 600,000 deaths, mostly in children under 5 years of age. For the past decade, artemisinin-based combination therapies have been recommended by the World Health Organization as the standard malaria treatment worldwide. Their widespread use has led to the development of artemisinin resistance in the form of delayed parasite clearance, alongside the rise of partner drug resistance. There is an urgent need to develop and deploy new antimalarial agents with novel targets and mechanisms of action. Here, we report a new and potent antimalarial compound, known as MMV1557817 , and show that it targets multiple stages of the malaria parasite lifecycle, is active in a preliminary mouse malaria model, and has a novel mechanism of action. Excitingly, resistance to MMV15578117 appears to be self-limiting, suggesting that development of the compound may provide a new class of antimalarial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Deakin University, Geelong, Australia.
- The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Australia.
- Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Australia.
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.
- Discovery Biology, Centre for Cellular Phenomics, Griffith University, Nathan, Queensland, Australia.
- Global Health and Tropical Medicine Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
ORCID-Profile: Rebecca C S Edgar, Sandra Duffy, Vicky M Avery, Darren J Creek, Tania F de Koning-Ward, Peter J Scammells, Sheena McGowan
Förderung
- DHAC | National Health and Medical Research Council (NHMRC)
- Therapeutic Innovation Australia (TIA)
Zitieren
APA
Edgar, R. C. S., Malcolm, T. R., Siddiqui, G., Giannangelo, C., Counihan, N. A., Challis, M., Duffy, S., Chowdhury, M., Marfurt, J., Dans, M., Wirjanata, G., Noviyanti, R., Daware, K., Suraweera, C. D., Price, R. N., Wittlin, S., Avery, V. M., Drinkwater, N., Charman, S. A., …, & McGowan, S. (2024). On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity. mBio. https://doi.org/10.1128/mbio.00966-24
Vancouver
Edgar RCS, Malcolm TR, Siddiqui G, Giannangelo C, Counihan NA, Challis M, et al. On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity. mBio. 2024. doi:10.1128/mbio.00966-24
BibTeX
@article{Edgar2024,
author = {Edgar, Rebecca C S and Malcolm, Tess R and Siddiqui, Ghizal and Giannangelo, Carlo and Counihan, Natalie A and Challis, Matthew and Duffy, Sandra and Chowdhury, Mrittika and Marfurt, Jutta and Dans, Madeline and Wirjanata, Grennady and Noviyanti, Rintis and Daware, Kajal and Suraweera, Chathura D and Price, Ric N and Wittlin, Sergio and Avery, Vicky M and Drinkwater, Nyssa and Charman, Susan A and Creek, Darren J and de Koning-Ward, Tania F and Scammells, Peter J and McGowan, Sheena},
title = {On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity},
journal = {mBio},
year = {2024},
doi = {10.1128/mbio.00966-24}
}
EUVIMED